SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在表达NY-ESO-1的NSCLC患者中进行的这项研究有望证明：1)PMED接种的NY-ESO-1质粒DNA(PPJV7611)癌症疫苗可以以治疗相关不良反应的频率、严重程度和持续时间为终点安全接种；2)通过检测NY-ESO-1特异性抗体、NY-ESO-1特异性CD8+和CD4+细胞以及迟发型超敏反应[DTH]，该疫苗可诱导对NY-ESO-1的细胞和体液免疫反应。3)记录可测量疾病患者在接种PMEd接种NY-ESO-1质粒DNA(PPJV7611)肿瘤疫苗后的肿瘤反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study in the targeted populaton of NSCLC patients expressing NY-ESO-1 expected to demonstrate that 1) NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by PMED can be safely administered using frequency, severity, and duration of treatment-related adverse effects as endpoints, 2) the vaccine elicits a cellular and humoral immune response to NY-ESO-1 by determination of NY-ESO-1 specific antibody, NY-ESO-1 specific CD8+ and CD4+ cells and delayed-type-hypersensitivity [DTH], and 3) to document tumor response in patients with measurable disease after receiving NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine administered by PMED.